
Knight Therapeutics Inc. (TSX:GUD) (OTC:KHTRF) entered into exclusive license and supply agreements with Rigel Pharmaceuticals (NASDAQ:RIGL), securing the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE (fostamatinib disodium hexahydrate) and in Europe under the brand name TAVLESSE for the treatment of chronic immune thrombocytopenia (ITP).